skip to primary navigationskip to content

Twist Bioscience Seminar: You Design It, We Build It

Emily Leproust, Ph.D. serves as CEO, co-founder and director of Twist Bioscience and will describe Twist's DNA synthesis approach and what that can enable for your research.
When Nov 07, 2017
from 03:00 PM to 07:00 PM
Where Lecture Theatre, Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, Cambridge
Add event to calendar vCal

This event is organised by CRUK Cambridge Cancer Institute and you need to register here to attend!

From Prof Greg Hannon: 

I would like to call your attention to a seminar to be given by Emily LeProust at the CI on November 7. Emily (see the bio below) has long been a pioneer in the synthesis of complex oligonucleotide libraries, and I had the privilege of collaborating with her during her time at Agilent. More recently, she founded Twist Bioscience ( to exploit complex oligo libraries and other technologies for large scale gene synthesis and synthetic biology. 

If you come to the talk, I think you will be astounded, as was I, at what they can enable. If the science alone is not sufficient enticement, there will be a reception afterwards, which I am sure will be both enjoyable and thought provoking. 

Please register at to attend.

Emily Leproust, Ph.D. serves as CEO, co-founder and director of Twist Bioscience. As an early pioneer in the high throughput synthesis and sequencing of DNA, Dr. Leproust is disrupting the process of gene synthesis to enable the exponential growth of synthetic biology applications in multiple fields including medicine, DNA data storage, agricultural biology and industrial chemicals. In 2015, she was named one of _Foreign Policy’s_ 100 Leading Global Thinkers of 2015 for fast-tracking the building blocks of life, and _Fast Company_ named her one of the most creative people in business for synthesizing DNA faster than ever. Prior to Twist Bioscience, she held escalating positions at Agilent Technologies where she architected the successful SureSelect product line that lowered the cost of sequencing and elucidated dozens of Mendelian diseases. She also developed the Oligo Library Synthesis technology, where she initiated and led product and business development activities for the team. Dr. Leproust designed and developed multiple commercial synthesis platforms to streamline microarray manufacturing and fabrication. Prior to Agilent, she worked with Dr. X. Gao at the University of Houston developing DNA and RNA parallel synthesis processes on solid support, a project developed commercially by Xeotron Corporation. Dr. Leproust has published more than 34 peer-reviewed papers—many on applications of synthetic DNA, and is the author of numerous patents. She earned her Ph.D. in organic chemistry from the University of Houston and her M.Sc. in industrial chemistry from the Lyon School of Industrial Chemistry in France.


More information about this event…

Filed under:


The Synthetic Biology Strategic Research Initiative provides a hub for anyone interested in Synthetic Biology at the University of Cambridge, as well as commercial partners and external collaborators.